Avoid the use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients suffering from hypertension, cardiac insufficiency or chronic kidney disease – whatever their cause (including diabetes).

Do not administer erythropoiesis stimulating agents (ESA) to patients with chronic kidney disease (CKD) and spontaneous hemoglobin levels between 10 and 11 g/dL with no symptoms of anemization. The same applies to patients who have not been tested for blood ferritin levels and transferrin saturation, at least.

The target of 10-11 gr/dL of hemoglobin has been identified in patients with chronic kidney disease (CKD) as the hemoglobin level associated with a lower risk of complications, particularly for the cardiovascular system. It is also pointless to administer ESA without...